Literature DB >> 10331353

Multifocal acquired demyelinating sensory and motor neuropathy: the Lewis-Sumner syndrome.

D S Saperstein1, A A Amato, G I Wolfe, J S Katz, S P Nations, C E Jackson, W W Bryan, D K Burns, R J Barohn.   

Abstract

We report 11 patients with multifocal acquired demyelinating sensory and motor (MADSAM) neuropathy, defined clinically by a multifocal pattern of motor and sensory loss, with nerve conduction studies showing conduction block and other features of demyelination. The clinical, laboratory, and histological features of these patients were contrasted with those of 16 patients with multifocal motor neuropathy (MMN). Eighty-two percent of MADSAM neuropathy patients had elevated protein concentrations in the cerebrospinal fluid, compared with 9% of the MMN patients (P < 0.001). No MADSAM neuropathy patient had elevated anti-GM1 antibody titers, compared with 56% of MMN patients (P < 0.01). In contrast to the subtle abnormalities described for MMN, MADSAM neuropathy patients had prominent demyelination on sensory nerve biopsies. Response to intravenous immunoglobulin treatment was similar in both groups (P = 1.0). Multifocal motor neuropathy patients typically do not respond to prednisone, but 3 of 6 MADSAM neuropathy patients improved with prednisone. MADSAM neuropathy more closely resembles chronic inflammatory demyelinating polyneuropathy and probably represents an asymmetrical variant. Given their different clinical patterns and responses to treatment, it is important to distinguish between MADSAM neuropathy and MMN.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10331353     DOI: 10.1002/(sici)1097-4598(199905)22:5<560::aid-mus2>3.0.co;2-q

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  28 in total

Review 1.  Management of chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Richard A C Hughes
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 2.  Multifocal motor neuropathy: diagnosis, pathogenesis and treatment strategies.

Authors:  Lotte Vlam; W-Ludo van der Pol; Elisabeth A Cats; Dirk C Straver; Sanneke Piepers; Hessel Franssen; Leonard H van den Berg
Journal:  Nat Rev Neurol       Date:  2011-11-22       Impact factor: 42.937

Review 3.  Inflammatory neuropathies.

Authors:  Hannah R Briemberg; Anthony A Amato
Journal:  Curr Neurol Neurosci Rep       Date:  2005-02       Impact factor: 5.081

Review 4.  Diagnosis of acute neuropathies.

Authors:  Clarissa Crone; Christian Krarup
Journal:  J Neurol       Date:  2007-09-21       Impact factor: 4.849

5.  Long term prognosis of chronic inflammatory demyelinating polyneuropathy: a five year follow up of 38 cases.

Authors:  S Kuwabara; S Misawa; M Mori; N Tamura; M Kubota; T Hattori
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-01       Impact factor: 10.154

Review 6.  Advances in the diagnosis, pathogenesis and treatment of CIDP.

Authors:  Marinos C Dalakas
Journal:  Nat Rev Neurol       Date:  2011-08-16       Impact factor: 42.937

Review 7.  Chronic inflammatory demyelinating polyneuropathies: current treatment strategies.

Authors:  Thomas B Toothaker; Thomas H Brannagan
Journal:  Curr Neurol Neurosci Rep       Date:  2007-01       Impact factor: 5.081

8.  A case of Lewis-Sumner syndrome showing dramatic improvement after plasma exchange.

Authors:  Young-Eun Park; Ji-Won Yook; Dae-Seong Kim
Journal:  J Korean Med Sci       Date:  2010-06-16       Impact factor: 2.153

9.  Increased pro-inflammatory cytokine gene expression in peripheral blood mononuclear cells of patients with polyneuropathies.

Authors:  Melissa Langjahr; Anna-Lena Schubert; Claudia Sommer; Nurcan Üçeyler
Journal:  J Neurol       Date:  2018-01-25       Impact factor: 4.849

Review 10.  Distinguish CIDP with autoantibody from that without autoantibody: pathogenesis, histopathology, and clinical features.

Authors:  Lisha Tang; Qianyi Huang; Zhen Qin; Xiangqi Tang
Journal:  J Neurol       Date:  2020-04-07       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.